Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150


Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.

Myers MV, Manning HC, Coffey RJ, Liebler DC.

Mol Cell Proteomics. 2012 Feb;11(2):M111.015222. doi: 10.1074/mcp.M111.015222. Epub 2011 Dec 5.


Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.


Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.

Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J.

Cancer Lett. 2009 Oct 8;283(2):135-42. doi: 10.1016/j.canlet.2009.03.034. Epub 2009 Apr 19.


Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2004 Jan 15;10(2):784-93.


Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.

Amaro A, Mirisola V, Angelini G, Musso A, Tosetti F, Esposito AI, Perri P, Lanza F, Nasciuti F, Mosci C, Puzone R, Salvi S, Truini M, Poggi A, Pfeffer U.

Eur J Cancer. 2013 Oct;49(15):3353-65. doi: 10.1016/j.ejca.2013.06.011. Epub 2013 Jul 9.


The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.


HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR.

Clin Cancer Res. 2011 Feb 1;17(3):472-82. doi: 10.1158/1078-0432.CCR-10-0568. Epub 2010 Nov 22.


Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.

Festuccia C, Gravina GL, Millimaggi D, Muzi P, Speca S, Ricevuto E, Vicentini C, Bologna M.

Oncol Rep. 2007 Aug;18(2):503-11.


Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.

PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.


Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.

Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. doi: 10.1158/1055-9965.EPI-09-0937. Epub 2010 Jan 19.


Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.

Cancer Biol Ther. 2011 Sep 1;12(5):436-46. Epub 2011 Sep 1.


Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.

Feng YH, Tsao CJ, Wu CL, Chang JG, Lu PJ, Yeh KT, Shieh GS, Shiau AL, Lee JC.

Cancer Sci. 2010 Sep;101(9):2033-8. doi: 10.1111/j.1349-7006.2010.01637.x.


Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.


Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR.

Clin Cancer Res. 2012 Sep 15;18(18):4986-96. doi: 10.1158/1078-0432.CCR-12-0792. Epub 2012 Jul 23.


Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA.

J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94.


Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.

Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M.

Microvasc Res. 2008 May;76(1):15-22. doi: 10.1016/j.mvr.2008.01.002. Epub 2008 Mar 18.


PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM.

Cancer Res. 2008 Mar 15;68(6):1953-61. doi: 10.1158/0008-5472.CAN-07-5659. Erratum in: Cancer Res. 2009 Dec 1;69(23):9156. Cancer Res. 2008 Aug 15;68(16):6859. Soler, Roman Perez [corrected to Perez-Soler, Roman].


Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR.

Clin Cancer Res. 2010 May 1;16(9):2571-9. doi: 10.1158/1078-0432.CCR-10-0333. Epub 2010 Apr 13.

Supplemental Content

Support Center